Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease

1. Socinski, M.A.
2. Kaye, F.J.
3. Spigel, D.R.
4. Kudrik, F.J.
5. Ponce, S.
6. Ellis, P.M.
7. Majem, M.
8. Lorigan, P.
9. Gandhi, L.
10. Gutierrez, M.E.
11. Nepert, D.
12. Corral, J.
13. Ares, L.P.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/J.CLLC.2016.09.002 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus